Inmune Bio, Inc.

INMBSEC EDGAR

Biological Products, (No Diagnostic Substances)(NV)CIK: 1711754

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	$155.0K	$374.0K	$181.0K	$11.0K	$10.9K
Research and Development Expense	$20.3M	$17.1M	$20.5M	$5.9M	$3.3M
Operating Expenses	$29.9M	$26.3M	$29.3M	$12.2M	$7.8M
Operating Income (Loss)	-$29.7M	-$26.0M	-$29.2M	-$12.2M	-$7.8M
Interest Expense	$2.3M	$2.0M	—	—	—
Nonoperating Income (Expense)	-$267.0K	—	—	$129.0K	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$30.0M	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$57.0M	$81.8M	$99.9M	$40.7M	$24.5M
Assets, Current	$39.9M	$64.7M	$82.6M	$24.0M	$7.8M
Cash and Cash Equivalents, at Carrying Value	$35.8M	$52.2M	$74.8M	$7.0M	$186.2K
Accounts Receivable, after Allowance for Credit Loss, Current	$1.9M	—	—	—	—
Liabilities	$18.9M	$21.7M	$19.7M	$1.9M	$860.5K
Liabilities, Current	$18.5M	$10.9M	$4.4M	$1.8M	$700.4K
Long-term Debt	$15.0M	—	$15.0M	$15.0M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$12.0M	-$22.7M	-$28.5M	-$8.9M	-$5.4M
Net Cash Provided by (Used in) Investing Activities	—	—	-$15.0M	-$15.0M	—
Net Cash Provided by (Used in) Financing Activities	-$4.2M	$729.0K	$96.4M	$23.9M	$12.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)